GenPath logo in conjunction with oncology

OnkoSight AdvancedTM Features

OnkoSight AdvancedTM next-generation sequencing is capable of empowering physicians with advanced genetic sequencing to improve cancer patient management.

OnkoSight AdvancedTM informs all clinically relevant aspects of routine oncology practice:

  • Diagnoses
  • Helps stratify patients into different risk groups
  • Tailors targeted treatment strategies


High Clinical Utility

Targeted, tumor-type specific NGS panel includes all gene mutations with clear therapeutic, diagnostic, or prognostic guidelines and those with established disease-associations for which there are clinical trial options.

Industry-leading Turnaround Time

OnkoSight AdvancedTM provides actionable results in about 4-10 days from receipt of specimen at the laboratory for timely initiation of medical management.

Minimal DNA Requirement

OnkoSight AdvancedTM effectively utilize tumor samples. The DNA input requirement for OnkoSight AdvancedTM (40ng) is approximately half that of other commercially available NGS assays employing similar hybrid capture NGS technology, and utilize unique molecular indices to reduce sequencing error by up to 10-20 fold.

Cost Effective

Optimize efficiency and provide significant cost saving over similar tests in the market.

Customized NGS Reporting

Clinicopathologic data is routinely factored into final interpretations for all detected variants, providing tailored, patient-specific reports. Reporting of detected variants include therapeutic associations with FDA-approved therapies, and reported and classified following AMP/ASCO/CAP recommendations.

OnkoSight Advanced Sample Report

Technical Specifications:

Limit of Detection 4% variant allele frequency for SNVs and small indels
Preferred FFPE DNA Input 40ng DNA
Panel Size 1.94 Megabases
©2023 GenPath, a division of BioReference Laboratories, an OPKO Health Inc. Company